Pneumococcal vaccination of children

Seminars in Pediatric Infectious Diseases

Volumn 13, Issue 3, 2002, Pages 155-164

  Overturf, Gary D ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE;

ANTIBODY RESPONSE; ARTICLE; CHILDHOOD DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; FEVER; HIGH RISK POPULATION; HUMAN; IMMUNOLOGICAL MEMORY; INFECTION PREVENTION; IRRITABILITY; STREPTOCOCCUS INFECTION; TREATMENT INDICATION; VACCINATION; VOMITING; CHILD; ECONOMICS; IMMUNOLOGY; INFANT; METHODOLOGY; PRESCHOOL CHILD; REVIEW; RISK FACTOR; STANDARD; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOLOGIC MEMORY; INFANT; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINATION;

EID: 0036628937     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/spid.2002.125858     Document Type: Article

References (56)

1. Intramuscular oral antibiotic therapy for the prevention of meningitis and other bacterial sequelae in young, febrile children at risk for occult bacteremia
2. Technical report: Prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis
3. Infections and immunizations of children with sickle cell disease
4. Bacteremia in sickle hemoglobinopathies
5. Bacterial meningitis and septiccmia in sickle cell disease
6. Fatal pneumococcal septicemia in hemoglobin SC disease
7. Sepsis and congenital asplenia
8. Invasive pncumococcal infections in children with asplenia
9. Prophylaxis with oral penicillin in children with sickle cell anemia: A randomized trial
10. Pneumococcal septicemia despite pneumococcal vaccine and prescription of penicillin prophylaxis in children with sickle cell anemia
11. Bacterial infection in the acquired human immunodeficiency virus-infected children
12. Invasive bacterial infections in children born to women infected with human immunodeficiency virus type 1
13. Invasive pneumococcal infections in human immunodeficiency virus-infected children
14. Invasive pneumococcocal disease among infected and uninfected children of mothers with human immunodeficiency virus infection
15. High incidence rates of invasive pneumococcal disease in the White Moutain Apache population
16. The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990: Ethnic differences and opportunities for prevention
17. Risk factors for primary invasive pneumococcal disease among children in Finland
18. Risk factors for invasive pneumococcal disease in children: A population-based control study in North America
19. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio
20. Invasive disease due to a multiply resistant Streptococcocus pneumoniae in a Houston, Tex day-care center
21. A cluster of invasive pneumococcal disease in young children in child care
22. Carriage of a multi-drug-resistant Streptococcus pneumoniae and impact of chemoprophylaxis during an outbreak of meningitis at a day care center
23. Potential interventions for the prevention of childhood pneumonia: Geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children: Implications for vaccine strategies
24. Epidemiology of invasive pneumo-coccal disease in Southern California: ImpIications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial
25. Invasive Streptococcus pneumoniae infection in Latin American Children: Results of the Pan American Health Organization Surveillance Study
26. Serotypes of respiratory isolates of Streptococcus pneumoniae compared with the capsular types included in the current pneumococcal vaccine
27. Assessment of the pneumococcal polysaccharide. IV. Efficacy of pneumococcal vaccine in infants and children
28. Pneumococcal conjugate vaccines
29. Recommendation for using pneumococcal vaccine in children
30. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practice (ACIP)
31. Pneumococcal disease after pneumococcal vaccination: An alternative method to estimate the efficacy of pneumococcal vaccine
32. Efficacy of pneumococcal vaccination against recurrent otitis media: Preliminary results of a field trial in Finland
33. Vaccination against Streptococcus pneumoniae in childhood: Lack of demonstrable benefit in young Australian children
34. Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease
35. Policy statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis
36. 197 in US infants
37. 197 conjugate vaccine in infants and toddlers
38. Minimum protective serum concentrations of pneumococcal anti-capsular anti-bodies in infant rats
39. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugate and boosted with polysaccharide or conjugate vaccines
40. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine
41. Marked differences in pneumococcal carriage and resistance patterns between clay care centers located within a small area
42. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
43. Efficacy of a pneumococcal conjugate vaccine against acute otitis media
44. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease
45. Effect of human immunodeficiency virus type I infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: Results from a randomized trial
46. Safety and immunogenicity of three closes of a five valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection
47. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children
48. Preventing pneumococcal disease among infants and children: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
49. Recombinant exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of Streptococcus pneumonia
50. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae
51. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA
52. Natural development of antibodies to pneumococcal surface protein A, pneumococcal adhesin A and pneumolysin in relation to pneumococcal carriage and acute otitis media
53. Protection against baeteremic pneumococcal infection by antibody to pneumolysin